BASF to Build New World-Scale Plant for Specialty Amines in Ludwigshafen
BASF is building a new world-scale plant for the production of specialty amines in Ludwigshafen. Start-up of the facility with a total annual capacity of about 12,000 metric tons is scheduled for 2015. The product range of this flexible multi-product plant comprises 15 amines for different applications. The major applications are in the construction, automotive, crop protection and pharmaceutical industries. With this new facility, BASF is expanding its global production network of amines with plants in Ludwigshafen and Schwarzheide in Germany; Antwerp, Belgium; Geismar, Louisiana; and Nanjing, China.
“With the new plant we are responding to our customers’ demand for specialty amines, particularly in Europe,” said Sanjeev Gandhi, President, BASF Intermediates division. “We have decades of experience in developing and manufacturing amines, and with the new plant we are reinforcing our global leadership position in these versatile intermediates.”
“This facility enables us to react flexibly to changes in the demand of individual products. We will also use it to produce commercial quantities of new products from our innovation pipeline,” said Dr Christoph Wegner, head of the regional business unit Amines Europe within BASF’s Intermediates division. “Being integrated into the BASF Verbund at the Ludwigshafen site allows us to scale up products from R&D to pilot scale and to commercial production in this new multi-product plant for our customers.”
BASF had announced in March that it is building another new multi-product plant for the production of specialty amines at the BASF Verbund site in Nanjing, China. The main products of this plant, which is due to start-up operations in 2015, will be dimethylaminopropylamine (DMAPA) and polyetheramine (PEA).
With about 200 different amines, BASF has the world’s most diverse portfolio of this type of chemical intermediates. Along with alkyl-, alkanol-, alkoxyalkylamines, the company offers heterocyclic and aromatic as well as specialty amines. The range is completed by an expanding portfolio of chiral amines of high optical and chemical purity. The versatile products are used mainly to manufacture process chemicals, pharmaceuticals and crop protection products, as well as cosmetic products and detergents. They also serve to produce coatings, special plastics, composites and special fibers.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.